{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044572","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.284329+00:00","generated_at":"2026-05-30T02:34:20.087092+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enveric out-licenses EB-002 to MycoMedica for up to $62M milestones plus royalties","bullets":["Exclusive global license for EB-002 (EVM201) to treat neuropsychiatric disorders.","Enveric receives modest upfront payments; eligible for up to $62M in development/sales milestones.","Tiered single-digit royalties on all future sales; MycoMedica has buyout options.","Enveric will focus resources on lead candidate EB-003, targeting IND filing in 2025.","MycoMedica assumes all future preclinical, clinical, and commercial development costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044572","json":"https://secwatch.observer/filing/0001493152-24-044572.json","markdown":"https://secwatch.observer/filing/0001493152-24-044572.md","text":"https://secwatch.observer/filing/0001493152-24-044572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224044572/0001493152-24-044572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224044572/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:34:20.087092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}